Winder Laboratories Initiates Nationwide Recall of Morphine Sulfate Oral Solution Due to Labeling Error
Winder Laboratories, LLC has initiated a voluntary Class III recall of 3,528 bottles of Morphine Sulfate Oral Solution (ANDA211454) nationwide in the U.S. The recall (D-0223-2026) stems from a critical mispack where carton labels incorrectly stated bottle sizes. This event underscores the persistent need for robust quality control in pharmaceutical packaging operations.
FDA-Initiated Recall: Winder Laboratories' Morphine Sulfate Oral Solution Mispack
Winder Laboratories, LLC, based in Winder, GA, United States, has initiated a voluntary Class III recall for its Morphine Sulfate Oral Solution, specifically the 100 mg / 5 mL (20 mg/mL) concentration in 30 mL bottles. This action, identified as recall number D-0223-2026, was initiated on November 26, 2025, and affects 3,528 bottles from lot 1312405, which has an expiration date of September 28, 2027. The primary reason for this recall is a "Correct Labeled Product Mispack," where the size stated on the carton label did not accurately match the size of the bottle contained within. This critical discrepancy, involving product NDC 75826-131-01 and associated with ANDA211454, impacts distribution nationwide across the U.S. For procurement and quality assurance teams sourcing Morphine Sulfate or other oral solutions from Winder Laboratories, LLC, this event necessitates an immediate review of inventory and supply chain security protocols. A mislabeling incident, even if Class III, signals potential vulnerabilities in packaging and labeling quality control processes, which could escalate to more significant compliance issues if not promptly addressed.
Commercial Impact of Morphine Sulfate Supply Disruption in the U.S.
The nationwide distribution of Winder Laboratories, LLC's Morphine Sulfate Oral Solution means this recall (D-0223-2026) has direct implications for U.S. pharmaceutical distributors, pharmacies, and healthcare providers. As a human prescription drug administered orally, Morphine Sulfate is a critical analgesic, and any disruption, even for a specific lot like 1312405, can affect patient access and inventory management for controlled substances. While the recalled quantity of 3,528 30 mL bottles might appear limited, the impact on a tightly controlled supply chain can be disproportionate. Supply chain VPs and regulatory affairs heads must ensure robust procedures for identifying, quarantining, and returning affected product. Furthermore, business development executives should assess the competitive landscape for generic Morphine Sulfate, noting that any supplier exhibiting similar packaging control weaknesses could face comparable regulatory actions, potentially creating market opportunities for more compliant manufacturers. The ongoing status of this recall mandates continuous monitoring by all stakeholders.
Regulatory Classification and Compliance Implications for Pharmaceutical Manufacturers
The FDA classified this Winder Laboratories, LLC recall as Class III, indicating that exposure to the violative product is not likely to cause adverse health consequences. This classification, confirmed on December 9, 2025, aligns with the nature of a packaging mislabeling rather than a direct product quality or safety defect. The recall was voluntarily initiated by Winder Laboratories, LLC, demonstrating the firm's responsibility in addressing the issue. However, regulatory affairs and quality control departments across the industry must recognize that even voluntary, Class III recalls signify a deviation from Good Manufacturing Practices (GMP), particularly concerning packaging and labeling controls. For manufacturers of controlled substances like Morphine Sulfate, adherence to stringent labeling accuracy is paramount not only for patient safety but also for maintaining regulatory standing and avoiding the substantial costs associated with product recalls and potential reputational damage. This event serves as a reminder that FDA oversight extends to all aspects of pharmaceutical production, including packaging integrity.
Broader Regulatory Environment and Quality Control Scrutiny
The recall of Morphine Sulfate Oral Solution by Winder Laboratories, LLC occurs within a period of sustained and rigorous FDA scrutiny across the pharmaceutical and life sciences sectors. This incident, though specific to packaging, reflects a broader regulatory environment where quality control failures are met with decisive action. Recent parallel events highlight this trend; for instance, Essential Wellness Pharma faced a Class II recall for its Progesterone Injection due to sterility assurance failures, and Amgen's Tavneos market future was subject to an FDA hearing concerning independent data review. These diverse regulatory actions underscore that procurement directors and supply chain VPs must adopt a comprehensive risk management approach. Proactive measures, including thorough supplier qualification, continuous auditing of manufacturing and packaging processes, and strategic diversification of supply chains, are essential to mitigate potential disruptions arising from quality control issues or data integrity concerns, regardless of the therapeutic area or product type.